Medicago awarded $21 million from the U.S. Department of Defense
Medicago to develop a vaccine facility in Research Triangle Park, North Carolina
Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency (DARPA), Broad Agency Announcement (BAA), Defense Sciences Research & Technology to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the U.S.A. under a Technology Investment Agreement.
Medicago will develop a 90,000-square-foot cGMP facility in Research Triangle Park (RTP), North Carolina. This state-of-the-art facility will be a large, cost-effective and scaled-up facility for Medicago's VLP plant-based vaccine technology for the delivery of cGMP-grade vaccine. Medicago will scale-up and automate its cGMP process to demonstrate its capacity to produce 10 million doses/month of influenza vaccines with the potential for further expansion in the future.
This DARPA project is an accelerated and integrated effort to deliver effective production of pandemic influenza in the U.S.A. The Accelerated Manufacture of Pharmaceuticals (AMP) program seeks to identify new ways to produce large amounts of high quality vaccine protein in less than 3 months in response to emerging and novel biologic threats. The strategic collaboration is a $42M project in which DARPA contributes $21M, Medicago $7.5M and Alexandria Real Estate Equities Inc. ('Alexandria') $13.5M.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
These boosts are made for walkin' - Study reveals that movement kicks visual system into higher gear

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Biogen Idec and Swedish Orphan Biovitrum receive opinion from EMA on pediatric plan for long-lasting hemophilia B therapy
New technique for testing drugs to treat cystic fibrosis and epilepsy
Acambis expands manufacturing capability with acquisition of US-based fill/finish facility
InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
Abbott to Fund Pharmaceutical and Diagnostics Research at the Weizmann Institute of Science
